GSK Says Early-Stage Trial Shows Lung-Cancer Drug Benefit

GSK said an early-stage global trial of risvutatug rezetec, licensed from China's Hansoh Pharmaceutical Group, showed tumors shrank or disappeared in a majority of patients.